Precision BioSciences has developed PBGENE-HBV, the only therapy in clinical trials specifically designed to eliminate the root cause of chronic hepatitis B viral replication by targeting the cccDNA and integrated HBV DNA.

PBGENE-HBV
Find resources and learn more about 
chronic hepatitis B and PBGENE-HBV >

ELIMINATE-B is a phase 1, open-label, first-in-human dose-finding and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.

ClinicalTrials.gov identifier 
NCT06680232

To connect with one of our study sites, please contact our Patient Advocacy Team at:  
patientadvocacy@precisionbiosciences.com

HBV Currently Lacks a Curative Treatment

Hepatitis B is a leading cause of morbidity in the US and death globally, with no current curative options

> 2.4 million
HBV infections in the US1,2

> 300 million
cHBV infections globally1,2

An estimated

15% to 40% of patients

with HBV infections may develop complications, such as cirrhosis, liver failure, or liver cancer, which account for the majority of HBV-related deaths.3

Current HBV treatments require lifelong chronic treatment that may result in viral suppression by reducing circulating HBV DNA, but these therapies do not eradicate HBV cccDNA and therefore rarely lead to cure. Up to 500,000 patients with HBV develop hepatocellular carcinoma (HCC) annually.

PBGENE-HBV:

PBGENE-HBV, the first gene editing therapy designed to treat chronic Hepatitis B by directly targeting HBV cccDNA and integrated HBV DNA.





Reasons to Believe in Precision's Approach for HBV

[icon-box desc="PGBENE-HBV is the only clinical-stage program that targets the elimination of cccDNA, the sole source of viral replication, leading to sustained loss of HBV DNA and other downstream viral transcripts" icon_type="custom" icon_img="3888" size="100" pos="left" el_class="icon-box"][icon-box desc="Substantial viral marker reductions and paired biopsy data from dosed patients provide first evidence consistent with direct viral DNA gene editing" icon_type="custom" icon_img="4234" size="100" pos="left" el_class="icon-box"]
[icon-box desc="Designed as a potentially curative treatment for chronic hepatitis B infection" icon_type="custom" icon_img="3886" size="100" pos="left" el_class="icon-box"][icon-box desc="Clinical data to date demonstrate a favorable repeat-dosing safety profile and meaningful antiviral activity across the first 3 cohorts" icon_type="custom" icon_img="3885" size="100" pos="left" el_class="icon-box"]

Hear from Our Experts

An insightful exploration into the HBV landscape, how ARCUS gene editing is unique among other genetic modalities in development, details regarding the upcoming PBGENE-HBV clinical trial, and more.

  1. Nguyen MH et al. Clin Microbiol Rev. 2020;33(2); GSK public epidemiology estimates for cHBV.
  2. Trucchio, Patrick. “Hepatitis B Breakthrough Boom: Navigating a $450-$500 Billion Frontier”, H.C. Wainwright & Co. 14, Feb 2024.
  3. Centers for Disease Control and Prevention. Hepatitis B. CDC Yellow Book 2024: Health Information for International Travel. Accessed October 18, 2024.